価格表

在庫・価格 : 2026年04月15日 17時04分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Spike SARS-CoV-2 mRNA, Modified(5moU)
データシート
MRNA35-1000 OZBオズ バイオサイエンス
OZ Biosciences
1000 μg ご照会ください
(未発注)
追加

在庫・価格 : 2026年04月15日 17時04分 現在

Spike SARS-CoV-2 mRNA, Modified(5moU)

  • 商品コード:MRNA35-1000
  • メーカー:OZB
  • 包装:1000μg
  • 価格: ご照会ください
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Lokras AG., Adv Funct Mater. 2025 DOI: 10.1002/adfm.202505627

PubMed
2 Baghel S et al. Design of messenger RNA vaccines based on lipid-polymer hybrid nanoparticles. J Control Release 2025 Dec;388(Pt 2):114385
Baghel S et al
2025/01/01
PubMed
3 Kim SC et al. Human CD4 T cells are a functional target for lipid nanoparticle-based mRNA vaccines. mBio 2025 Nov;16(11):e0225425
Kim SC et al
2025/01/01
PubMed
4 Felgner J et al. Lipid Nanoparticle Development for A Fluvid mRNA Vaccine Targeting Seasonal Influenza and SARS-CoV-2. NPJ Vaccines 2025 Jun;10(1):123
Felgner J et al
2025/01/01
PubMed
5 Abe S et al. Impact of pre-existing anti-polyethylene glycol (PEG) IgM on biodistribution and humoral response of intramuscularly administered PEGylated mRNA loaded lipid nanoparticle. J Control Release 2025 Jul;383:113821
Abe S et al
2025/01/01
PubMed
6 Bakos T et al. mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions. Int J Mol Sci 2024 Mar;25(7)
Bakos T et al
2024/01/01
PubMed
  • No.: 1
  • 文献情報:
    Lokras AG., Adv Funct Mater. 2025 DOI: 10.1002/adfm.202505627

  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Baghel S et al. Design of messenger RNA vaccines based on lipid-polymer hybrid nanoparticles. J Control Release 2025 Dec;388(Pt 2):114385
    Baghel S et al
    2025/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Kim SC et al. Human CD4 T cells are a functional target for lipid nanoparticle-based mRNA vaccines. mBio 2025 Nov;16(11):e0225425
    Kim SC et al
    2025/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Felgner J et al. Lipid Nanoparticle Development for A Fluvid mRNA Vaccine Targeting Seasonal Influenza and SARS-CoV-2. NPJ Vaccines 2025 Jun;10(1):123
    Felgner J et al
    2025/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Abe S et al. Impact of pre-existing anti-polyethylene glycol (PEG) IgM on biodistribution and humoral response of intramuscularly administered PEGylated mRNA loaded lipid nanoparticle. J Control Release 2025 Jul;383:113821
    Abe S et al
    2025/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Bakos T et al. mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions. Int J Mol Sci 2024 Mar;25(7)
    Bakos T et al
    2024/01/01
  • 備考:
  • 参照:
    PubMed